Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01583530 · ClinicalTrials.gov registry record · Phase 1
Study of Belimumab Administered Subcutaneously to Healthy Subjects
A Phase 1 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT01583530: Completed Phase 1 study, sponsored by Human Genome Sciences.
NCT01583530 is a Phase 1 study that has completed, run by Human Genome Sciences. The registered enrollment target is 118 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01583530, a Phase 1 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.
Interventions
- BIOLOGICAL Single Dose Group: Belimumab IV 240 mg
- BIOLOGICAL Single Dose Group: Belimumab SC 2 x 120 mg
- BIOLOGICAL Single Dose Group: Belimumab SC 1 x 240 mg
- BIOLOGICAL Single Dose Group: Belimumab SC 1 x 200 mg
- BIOLOGICAL Multiple Dose Group: Belimumab SC 2 x 120 mg weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
What the finished NCT01583530 record still lists
NCT01583530 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 5 interventions - of which Single Dose Group: Belimumab IV 240 mg is the first listed.
NCT01583530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01583530 about?
NCT01583530 is a clinical study titled "Study of Belimumab Administered Subcutaneously to Healthy Subjects". The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.
What is the current status of trial NCT01583530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2011-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01583530?
The interventions under investigation include: Single Dose Group: Belimumab IV 240 mg (BIOLOGICAL), Single Dose Group: Belimumab SC 2 x 120 mg (BIOLOGICAL), Single Dose Group: Belimumab SC 1 x 240 mg (BIOLOGICAL), Single Dose Group: Belimumab SC 1 x 200 mg (BIOLOGICAL), Multiple Dose Group: Belimumab SC 2 x 120 mg weekly (BIOLOGICAL).
Who is sponsoring clinical trial NCT01583530?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01583530's enrollment target sits among peer trials
118 499th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia